阿哌沙班对新发多发性骨髓瘤患者凝血酶生成的影响比较 (ProApix)
预防性给予阿哌沙班对新发多发性骨髓瘤患者和接受全膝关节置换手术患者凝血酶生成的影响的比较
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study - APIXABOR - that measured the plasmatic concentration of Apixaban in patients with MM and treated with preventive dose has been conducted. The peak drug concentration was superior in MM plasma, as compared to non-myeloma patients under prophylaxis. Therefore, the present study evaluated whether differences in pharmacokinetics have an impact on pharmacodynamics (i.e. decrease in coagulability in MM patients as compared to non-MM patients undergoing a surgery for total knee replacement who also have VTE prophylaxis). In fine, this study may inform to better manage thromboprophylaxis in MM patients.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Emilie CHALAYER, MD
- 电话号码:33 (0)477822814
- 邮箱:emilie.chalayer@chu-st-etienne.fr
研究联系人备份
- 姓名:Florence RANCON
- 电话号码:33 (0)4 77 82 94 58
- 邮箱:florence.rancon@chu-st-etienne.fr
学习地点
-
-
-
Saint-Etienne、法国、42055
- 招聘中
- CHU de Saint-Etienne
-
副研究员:
- Julien LANOISELEE, MD
-
副研究员:
- Ludovic FOUILLET, MD
-
副研究员:
- Jean-Yves BIEN, MD
-
副研究员:
- Emmanuelle TAVERNIER, MD
-
接触:
- Emilie CHALAYER, MD
- 电话号码:33 (0)4 77 82 28 14
- 邮箱:emilie.chalayer@chu-st-etienne.fr
-
副研究员:
- Jérôme CORNILLON, MD
-
副研究员:
- Charlotte DOUBLET, MD
-
副研究员:
- Tiphany NEEL, MD
-
副研究员:
- Manon SAPET, MD
-
副研究员:
- Hugo THEVENET, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years old,
- Signed informed consent,
- Patient covered by a social security scheme.
- Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,
- Group 2 : patient requiring a surgery for total knee replacement, , with an indication of thromboprophylaxis with Apixaban.
Exclusion Criteria:
- Curative doses of anticoagulation treatment,
- Contra-indication to Apixaban,
- Pregnant or breastfeeding woman,
- Refusal to sign consent,
- Patient under legal protection.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Blood sampling of patients with de novo multiple myeloma
Description: Blood sampling of patients with de novo multiple myeloma |
Blood sampling Treatment by Apixaban |
|
实验性的:Blood sampling of patients undergoing total knee replacement
Description: Blood sampling of patients undergoing total knee replacement |
Blood sampling Treatment by Apixaban |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Endogenous Thrombin potential (nM.min)
大体时间:2 hours after Apixaban Treatment
|
Endogenous Thrombin potential (nM.min) as measured with MidiCAT method at the concentration peak 2 hours after 2.5mg Apixaban treatment |
2 hours after Apixaban Treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Apixaban concentration (ng/mL)
大体时间:Kinetics of 12 hours following Apixaban treatment in both groups
|
Apixaban concentration (ng/mL) as measured by mass spectrometry during 12 hours following Apixaban treatment (2.5mg) in both groups |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Endogenous Thrombin Potential
大体时间:Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Endogenous Thrombin Potential (nM.min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Lagtime
大体时间:Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Lagtime (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Time to peak
大体时间:Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Time to peak (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Thrombin peak
大体时间:Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Thrombin peak (M, Thrombin) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
合作者和调查者
调查人员
- 首席研究员:Emilie CHALAYER, MD、CHU de Saint-Etienne
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.